-$0.96 (-0.29%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.

Michel Vounatsos
Cambridge, Massachusetts

BIIB Key Statistics

Market Cap
Price-Earnings Ratio
Dividend Yield
Average Volume
High Today
Low Today
Open Price
52 Week High
52 Week Low


Simply Wall St18h

Biogen Inc. Insiders Increased Their Holdings

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to ment
BenzingaJul 23

Expert Ratings For Biogen - Biogen Idec

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 0 4 0 So
MarketWatchJul 22

Biogen, under pressure, tells investors it ‘stands by’ the FDA review process for its Alzheimer’s drug

Biogen executives sought to assure investors that the science behind its newly approved Alzheimer’s disease drug is firm despite ongoing questions about whether

BIIB Earnings

Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
$4.55 per share
$5.68 per share
Replay Earnings Call

More BIIB News

Yahoo FinanceJul 22

AT&T, Crocs, Biogen top Q2 estimates, Didi shares dip as China regulatory woes persist

Myles Udland, Brian Sozzi, and Julie Hyman breakdown more Q2 earnings, which include: AT&T stock rising as the company topped estimates due to a push from wirel
BenzingaJul 22

Biogen: Q2 Earnings Insights

Shares of Biogen (NASDAQ:BIIB) fell 0.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 44.64% over th
CNBCJul 22

Biogen's controversial Alzheimer’s drug generates $2 million in first few weeks after approval

Biogen's Alzheimer's drug, Adhulem, generated $2 million in revenue in the first few weeks of its approval, the company said Thursday in releasing its second-qu
CNBCJul 22

Stocks making the biggest moves premarket: Netgear, Unilever, Whirlpool, Crocs & more

Check out the companies making headlines before the bell Thursday: Netgear – Netgear shares plummeted 14.2% after the computer equipment maker reported lower-t
MarketWatchJul 22

Biogen's beats on earnings, says it's also brought in $2 million in sales of Alzheimer's drug

Shares of Biogen BIIB, +0.15% gained 1.6% in premarket trading on Thursday after the company beat expectations for the second quarter and disclosed that it's al
ReutersJul 22

Biogen defends Alzheimer's drug approval, reports $2 mln in early sales

A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian Snyder July 22 (Reuters) - Biogen Inc (BIIB.O) on Thursday sai
BenzingaJul 22

FDA Will Not Meet Goal Dates For Pfizer's Xeljanz, Abrocitinib Applications

Reuters (Reuters) -Biogen Inc on Thursday said getting hospitals and clinics to use its new Alzheimer's disease drug Aduhelm and insurers to reimburse it has b
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure